JP2002509153A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509153A5
JP2002509153A5 JP2000540142A JP2000540142A JP2002509153A5 JP 2002509153 A5 JP2002509153 A5 JP 2002509153A5 JP 2000540142 A JP2000540142 A JP 2000540142A JP 2000540142 A JP2000540142 A JP 2000540142A JP 2002509153 A5 JP2002509153 A5 JP 2002509153A5
Authority
JP
Japan
Prior art keywords
compound
interleukin
converting enzyme
treating
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000540142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002509153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/024848 external-priority patent/WO1999036426A1/en
Publication of JP2002509153A publication Critical patent/JP2002509153A/ja
Publication of JP2002509153A5 publication Critical patent/JP2002509153A5/ja
Abandoned legal-status Critical Current

Links

JP2000540142A 1998-01-20 1998-11-20 インターロイキン−1β変換酵素(ICE)のインビボ阻害剤としてのN−[2−(5−ベンジルオキシカルボニル−アミノ−6−オキソ−2−(4−フルオロフェニル)−1,6−ジヒドロ−1−ピリミジニル)アセトキシル]−L−アスパラギン酸アルデヒド Abandoned JP2002509153A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7191898P 1998-01-20 1998-01-20
US60/071,918 1998-01-20
PCT/US1998/024848 WO1999036426A1 (en) 1998-01-20 1998-11-20 N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETO- XYL]-L-ASPARTIC ACID ALDEHYDE AS AN IN VIVO INHIBITOR OF INTERLEUKIN-1β CONVERTING ENZYME (ICE)

Publications (2)

Publication Number Publication Date
JP2002509153A JP2002509153A (ja) 2002-03-26
JP2002509153A5 true JP2002509153A5 (cg-RX-API-DMAC7.html) 2006-01-19

Family

ID=22104428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000540142A Abandoned JP2002509153A (ja) 1998-01-20 1998-11-20 インターロイキン−1β変換酵素(ICE)のインビボ阻害剤としてのN−[2−(5−ベンジルオキシカルボニル−アミノ−6−オキソ−2−(4−フルオロフェニル)−1,6−ジヒドロ−1−ピリミジニル)アセトキシル]−L−アスパラギン酸アルデヒド

Country Status (11)

Country Link
EP (1) EP1049703B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002509153A (cg-RX-API-DMAC7.html)
AT (1) ATE232536T1 (cg-RX-API-DMAC7.html)
AU (1) AU1466399A (cg-RX-API-DMAC7.html)
CA (1) CA2309546A1 (cg-RX-API-DMAC7.html)
DE (1) DE69811404T2 (cg-RX-API-DMAC7.html)
DK (1) DK1049703T3 (cg-RX-API-DMAC7.html)
ES (1) ES2193589T3 (cg-RX-API-DMAC7.html)
PT (1) PT1049703E (cg-RX-API-DMAC7.html)
WO (1) WO1999036426A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA99369B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001068605A1 (en) 2000-03-13 2001-09-20 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE289299T1 (de) 2000-04-05 2005-03-15 Pharmacia Corp Polyzyclisch aryl und heteroaryl substituierte 4- pyronen verwendbar als selektive hemmung von dem koagulationsprozess
AU2001251315A1 (en) 2000-04-05 2001-10-23 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
EP1274676A2 (en) 2000-04-17 2003-01-15 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
WO2001087851A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CA2416248A1 (en) 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
CA2430037A1 (en) 2000-11-20 2002-05-30 Michael S. South Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
MXPA04003170A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion.
BR0213092A (pt) 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
AU2005223767B2 (en) 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
KR20080038369A (ko) 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
EP3836954B1 (en) 2018-08-13 2025-05-07 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
CN1118458C (zh) * 1994-03-31 2003-08-20 弗特克斯药品有限公司 作为白细胞介素抑制剂的嘧啶基衍生物

Similar Documents

Publication Publication Date Title
DE69936848D1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
EP1127579A3 (en) Method for increasing bioavailability of oral pharmaceutical compositions
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
TW200505901A (en) Muscarinic agonists
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PL321498A1 (en) Pharmaceutic agent for use against urine incontinence and method of obtaining (s)-desethyloxybutinine
EP1215173A4 (en) 12CaO * 7Al2O3: A COMPOSITION FOR THE PREPARATION OF CLASSES WITH ACTIVE OXYGEN SPECIES AND METHOD OF MAKING THE SAME
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
JP2002510633A5 (cg-RX-API-DMAC7.html)
MY119375A (en) Treatment of tinnitus using neuroprotective agents
JP2002518502A5 (cg-RX-API-DMAC7.html)
JP2002522501A5 (cg-RX-API-DMAC7.html)
MY118156A (en) Oral compositions of levosimendan.
JP2002520286A5 (cg-RX-API-DMAC7.html)
WO2002056745A3 (en) Method of treating parkinson's disease
WO2003015690A3 (en) Method for treating primary insomnia
JP2005513036A5 (cg-RX-API-DMAC7.html)
JP2002510653A5 (cg-RX-API-DMAC7.html)
JP2002537256A5 (cg-RX-API-DMAC7.html)
WO2002007715A3 (en) A method for treating celiac disease
EP0985414A3 (en) Method of treating glaucoma and ischemic retinopathy
AU1101301A (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use